Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now
Edesa Biotech Inc. surged 53.9% to finish Monday at $11.17 on Nasdaq, after opening the day at $7.38 and reaching as high as $11.87. Trading volume spiked close to 9.0 million shares—a notable swing for the small clinical-stage biotech, especially considering its most recent company news release was nearly a month old. This shift is drawing attention as traders revisit Edesa’s respiratory data from February, just ahead of a pair of May presentations set for the American Thoracic Society meetings. On its news page, Edesa highlights a March 31 respiratory conference update and a March 26 release on vitiligo, with the Phase 3 paridiprubart announcement still marked as Feb. 24.
